Peer-reviewed publications from Alpha Cancer Technologies researchers and collaborators
Pak, V. N., & Sherman, I. A. (2024). Comprehensive approach to cancer immunotherapy – Simultaneous targeting of myeloid-derived suppressor cells and cancer cells with AFP conjugates. Critical Reviews in Oncology/Hematology, 200, 104407. https://doi.org/10.1016/j.critrevonc.2024.104407
Griffin, R. J., Hill, W. A., Rossi, F., Boohaker, R., Stinson, K., & Sherman, I. (2023). High antitumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model. Cancer Cell International, 23(1), 60. https://doi.org/10.1186/s12935-023-02910-0
Sherman, I., Griffin, R. J., Chiu, R., et al. (2023). Efficacy and safety study of a novel alpha-fetoprotein (AFP)-maytansine conjugate in an ovarian xenograft model. Journal of Clinical Oncology, 41(16_suppl), e14570 (ASCO Annual Meeting abstract). https://doi.org/10.1200/JCO.2023.41.16_suppl.e14570
Alpha Cancer Technologies Inc. (2023). Preclinical efficacy and safety of ACT-903 in AFPR+ cancers. ASCO Annual Meeting 2023, Abstract e14566.
Pak, V. N. (2022). The perfect combination of the most powerful cancer immunotherapy with the best targeted chemotherapy. Cancer Therapy & Oncology International Journal, 20(5), 556050.
Pak, V. N. (2018). Selective targeting of myeloid-derived suppressor cells in cancer patients through AFP-binding receptors. Future Science OA, 4(1), FSO321. https://pmc.ncbi.nlm.nih.gov/articles/PMC6331696/
These publications describe preclinical research. ACT-903 has not yet been evaluated in humans.